Allianz Asset Management
ADMA icon

Allianz Asset Management’s ADMA Biologics ADMA Stock Holding History

Allianz Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,000
Closed -$474K – 1999
2025
Q4 		$474K Sell
26,000
-2,100
-7% -$35.4K ﹤0.01% 1844
2025
Q3 		$412K Sell
28,100
-21,900
-44% -$375K ﹤0.01% 1881
2025
Q2 		$911K Buy
50,000
+33,894
+210% +$691K ﹤0.01% 1691
2025
Q1 		$320K Buy
+16,106
New +$279K ﹤0.01% 2019
2024
Q4 		– Sell
-23,506
Closed -$470K – 2201
2024
Q3 		$470K Buy
+23,506
New +$366K ﹤0.01% 1866

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Allianz Asset Management's ADMA Position: Q1 2026 in Review

Allianz Asset Management sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 26,000 shares — an estimated $474K sold.

Allianz Asset Management first reported a position in ADMA in Q3 2024 and held it in 5 quarters. The position peaked at $911K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Allianz Asset Management reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Allianz Asset Management sold 26,000 ADMA Biologics shares in Q1 2026, an estimated $474K.
  • Allianz Asset Management first reported a position in ADMA Biologics in Q3 2024 and held it in 5 quarters.
  • Allianz Asset Management's ADMA Biologics position peaked at $911K in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.